The Precision Cancer Therapies Program, a multidisciplinary partnership between Ochsner and the Translational Genomics Research Institute (TGen)
, offers the region access to the latest in cancer therapeutics, research, and advanced diagnostics. This distinctive program combines Ochsner’s clinical expertise with the translational science strength of TGen, a non-profit biomedical research organization dedicated to conducting groundbreaking research with life-changing results.
Ochsner’s longstanding tradition of bringing physicians together to improve health outcomes continues today. The unique combination of patient care, research and education coupled with our multidisciplinary team sets our program apart. Ochsner physicians are at the forefront of modern molecular medicine, creating customized treatment plans based on the most up-to-date research and data.
Our innovative approach to cancer care involves not only cutting-edge technology, but also impactful clinical research and fundamental improvements in how cancer care is delivered. The Ochsner Precision Cancer Therapies Program (PCTP) is the region’s only clinical research program focused on early-phase clinical trials in patients with advanced cancer. This program makes Ochsner the clear choice for providing the very best cancer care available close to home.FACT: In 1939, Dr. Alton Ochsner conducted research on pulmonary malignancy and the link between smoking and lung cancer.